Joined May 2014
- Tweets1.1K
- Following392
- Followers1.5K
- Likes670
Peter Rossing retweeted
"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this"
"And if you don't do it, you're likely to become obsolete... because someone else will"
Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass
Last but certainly not least, Tuttle on FLOW and nephrology’s role in prescribing GLP-1s in kidney disease:
hcplive.com/view/kidney-comp…
Peter Rossing retweeted
Dear all,
I will defend my Ph.D. on Friday, November 8th at 2:30 PM at Herlev Hospital, and you are all more than welcome to drop by and listen in.
// Marie
@Stenodiabetes @HerlevGentofte @UCPH_Research @SUHhospital @RikkeBorg @FrederikPersson @DitteHansen7 @IBressendorff
Peter Rossing retweeted
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial | @NatureMedicine Spiro was often discontinued and no effect on outcome nature.com/articles/s41591-0…
Peter Rossing retweeted
The first simpub from the @CTCPR_ team during #ESC2024. The NUDGE-FLU-2 trial results in @NatureMedicine lead by @niklasdj1 👇
Electronic nudges for sustained influenza vaccination uptake in older adults (>65): the nationwide randomized NUDGE-FLU-2 trial
nature.com/articles/s41591-0…
Peter Rossing retweeted
Lovely final slide of the FINEHEART presentation from @mvaduganathan dedicated to the late Professor George Bakris #ESCCongress
Peter Rossing retweeted
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)!
Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF
Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund
bayer.com/media/en-us/finere…
Peter Rossing retweeted
Reminder: there is still time to share your feedback on the Scope of Work for the KDIGO Controversies Conference on the Relationship Between #Obesity and #CKD.
The Scope of Work and feedback form are available through Monday, August 5, and can be found on the conference website: kdigo.co/Obesity-CKD-Controv…
KDIGO thanks you for your time and insights.
Peter Rossing retweeted
Forskere fra hele kongeriget vil revolutionere behandlingen af #type1diabetes 👏 🌟 Det sker med studiet Steno 1, som netop er påbegyndt. Læs mere: sdcc.dk/presse-og-nyheder/ny… #steno1
Peter Rossing retweeted
@P_Rossing explaining rationale of FLOW - 1st dedicated kidney outcome trial of GLP1RA in DKD at #ADA2024
- Residual risk despite a/v Rx options
- Unclear about kidney outcomes if excl macroalbuminuria, and CV outcomes in eGFR<60
#ADASciSessions @AmDiabetesAssn @ADA_DiabetesPro
Peter Rossing retweeted
Are you attending APCN & KSN 2024 in Seoul? Don't miss the KDIGO sessions on #IgAN and #diabetes.
The KDIGO IgAN Session is on Saturday, June 15, from 10:30 to 12:00 KT in Room 6 (203). The session will be moderated by Seung Hyeok Han and Carol Pollock, with speakers Jonathan Barratt, Sydney Tang, Dan Cattran, and Sang Ho Lee.
The KDIGO Diabetes Session is on June 15 from 15:00 to 16:30 KT in Room 2 (103). The session will be chaired by Kathy Tuttle, with speakers Peter Rossing and Juliana Chan.
We hope to see you there!
#APCN2024 #APCNxKSN #KSN #APSN
Peter Rossing retweeted
🫀Day 2 of the 8th Annual Heart in Diabetes is here! Don't miss out on our exciting Dinner CME Symposium tonight at 6:30pm.
Check out our other sessions at heartindiabetes.com/agenda
#HID24 #HID2024 #8thHeartinDiabetes #CME #MedEd #MedicalEducation #MedicalConference #Diabetes
Peter Rossing retweeted
We're thrilled to announce the publication of the 7th @HeartinDiabetes Abstracts in the @AmericanHeartJournal, Volume 267, available online! Explore this rich collection at sciencedirect.com/journal/am…
Your chance to present at #HID24 awaits! Submit today: heartindiabetes.com/abstract…
Peter Rossing retweeted
Same mission, New name. Breakthrough T1D (formerly JDRF) is the world leader in T1D research, advocacy, and community support. Our new brand reflects our bold vision for a world without T1D. We are accelerating breakthroughs and building a movement for change. #BreakthroughT1D
Peter Rossing retweeted
Third @NEJM simultaneous publication at #ERA24 bravo @Tobias_B_Huber and team!!
Autoantibodies targeting nephrin in podocytopathies
nejm.org/doi/full/10.1056/NE…
Peter Rossing retweeted
The FLOW trial: #semaglutide significantly reduces the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney disease. #CKD @NEJM
nejm.org/doi/full/10.1056/NE…
Peter Rossing retweeted
Evolving treatment landscape in T2D and CKD by @P_Rossing
The figures of CKD!!!
New therapy algorithm has changed the landscape but there is still significant residual risk
@ERAkidney @SOMANEorg #ERA24 #FLOW
Peter Rossing retweeted
Thanks @Stenodiabetes for a great EDNSG conference. Two great days of learning and networking! #EDNSG2024
Peter Rossing retweeted
Chronic Kidney Disease Progression in Heart Failure: What We Know, Don’t Know, and Where to Next?
Our thoughts on GFR slope & assessment of kidney outcomes in heart failure trials, with @HeerspinkHiddo & @LAInker in @JACCJournals
sciencedirect.com/science/ar…
